Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers
- PMID: 2019191
- DOI: 10.1378/chest.99.5.1268
Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers
Abstract
Administering liposome-encapsulated drugs by aerosol is a feasible way of targeting drugs to the lungs. Prior to clinical application of aerosolized liposomes as drug carriers, their relative safety must be established. We evaluated the effects of inhaling nondrug-containing liposomes (15 and 150 mg of lipid per milliliter) for 1 h on pulmonary function and on oximetry in ten healthy nonsmoking volunteers. Spirometry was performed prior to and at intervals after inhalation, and subjects were monitored with pulse oximetry. Liposome inhalation was well tolerated, and no oxygen desaturation, decrements in pulmonary function, or side effects were noted. We conclude that inhalation of small particle aerosols of SPC liposomes produces no acute deleterious effects on pulmonary function in healthy subjects.
Similar articles
-
Pulmonary effects of chronic exposure to liposome aerosols in mice.Exp Lung Res. 1993 Jan-Mar;19(1):1-19. doi: 10.3109/01902149309071077. Exp Lung Res. 1993. PMID: 8440200
-
Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety.Chest. 1997 Feb;111(2):316-23. doi: 10.1378/chest.111.2.316. Chest. 1997. PMID: 9041975
-
Nebulization of liposomes. I. Effects of lipid composition.Pharm Res. 1990 Nov;7(11):1127-33. doi: 10.1023/a:1015924124180. Pharm Res. 1990. PMID: 2293210
-
Aerosol generation using nanometer liposome suspensions for pulmonary drug delivery applications.J Liposome Res. 2013 Dec;23(4):255-67. doi: 10.3109/08982104.2013.802332. Epub 2013 Jun 5. J Liposome Res. 2013. PMID: 23738780 Review.
-
Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.Med Princ Pract. 2016;25 Suppl 2(Suppl 2):60-72. doi: 10.1159/000445116. Epub 2016 Mar 2. Med Princ Pract. 2016. PMID: 26938856 Free PMC article. Review.
Cited by
-
Future developments in the pharmacotherapy of lung disease.Pharm Weekbl Sci. 1992 Aug 21;14(4A):221-3. doi: 10.1007/BF01962543. Pharm Weekbl Sci. 1992. PMID: 1437503 Review.
-
Effects of cationic liposome-DNA complexes on pulmonary surfactant function in vitro and in vivo.Lipids. 1997 Mar;32(3):247-53. doi: 10.1007/s11745-997-0031-2. Lipids. 1997. PMID: 9076661
-
Carrier Effect in Development of Rifampin Loaded Proliposome for Pulmonary Delivery: A Quality by Design Study.Adv Pharm Bull. 2022 Mar;12(2):336-345. doi: 10.34172/apb.2022.032. Epub 2021 May 18. Adv Pharm Bull. 2022. PMID: 35620341 Free PMC article.
-
Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.Int J Nanomedicine. 2008;3(1):1-19. Int J Nanomedicine. 2008. PMID: 18488412 Free PMC article. Review.
-
Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis.Front Pharmacol. 2020 Dec 11;11:607689. doi: 10.3389/fphar.2020.607689. eCollection 2020. Front Pharmacol. 2020. PMID: 33384604 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical